WO2012046945A2 - 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물 - Google Patents
당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물 Download PDFInfo
- Publication number
- WO2012046945A2 WO2012046945A2 PCT/KR2011/004836 KR2011004836W WO2012046945A2 WO 2012046945 A2 WO2012046945 A2 WO 2012046945A2 KR 2011004836 W KR2011004836 W KR 2011004836W WO 2012046945 A2 WO2012046945 A2 WO 2012046945A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound represented
- compound
- diabetes
- obesity
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 97
- 208000008589 Obesity Diseases 0.000 title claims abstract description 62
- 235000020824 obesity Nutrition 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 235000013305 food Nutrition 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 151
- 241001040161 Stereocaulon alpinum Species 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 38
- 239000004480 active ingredient Substances 0.000 claims abstract description 34
- 235000013376 functional food Nutrition 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 117
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- 239000002253 acid Substances 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- JHEWMLHQNRHTQX-UHFFFAOYSA-N 3-hydroxy-9-methoxy-6-oxo-7-(1-oxopentyl)-1-pentyl-2-benzo[b][1,4]benzodioxepincarboxylic acid Chemical compound O=C1OC2=CC(O)=C(C(O)=O)C(CCCCC)=C2OC2=CC(OC)=CC(C(=O)CCCC)=C21 JHEWMLHQNRHTQX-UHFFFAOYSA-N 0.000 claims description 26
- RQGOSSYDPQTDRA-UHFFFAOYSA-N Lobaric acid Natural products O=C1OC2=CC(O)=C(C(O)=O)C(CCCCC)=C2OC2=CC(OC)=C(C(=O)CCCC)C=C21 RQGOSSYDPQTDRA-UHFFFAOYSA-N 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 22
- -1 NaHCO 3 Substances 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 239000003929 acidic solution Substances 0.000 claims description 14
- 238000004007 reversed phase HPLC Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 11
- 238000004440 column chromatography Methods 0.000 claims description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 6
- 241001061260 Emmelichthys struhsakeri Species 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 abstract description 91
- 230000002401 inhibitory effect Effects 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 28
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 abstract description 9
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 abstract 3
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 88
- 239000011734 sodium Substances 0.000 description 75
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 69
- 229910052708 sodium Inorganic materials 0.000 description 69
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 67
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 56
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 56
- 239000008280 blood Substances 0.000 description 55
- 210000004369 blood Anatomy 0.000 description 55
- 239000008103 glucose Substances 0.000 description 55
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 238000007912 intraperitoneal administration Methods 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000011282 treatment Methods 0.000 description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 238000011160 research Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000007928 intraperitoneal injection Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- BWRBGHBJBQFFAW-UHFFFAOYSA-N lobarin Chemical compound OC1=CC(O)=C(C(O)=O)C(CCCCC)=C1OC1=CC(OC)=CC2=C1C(=O)OC2(O)CCCC BWRBGHBJBQFFAW-UHFFFAOYSA-N 0.000 description 11
- BWRBGHBJBQFFAW-VWLOTQADSA-N lobarin Natural products CCCCCc1c(Oc2cc(OC)cc3c2C(=O)O[C@@]3(O)CCCC)c(O)cc(O)c1C(=O)O BWRBGHBJBQFFAW-VWLOTQADSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000003178 anti-diabetic effect Effects 0.000 description 10
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- 101001087422 Homo sapiens Tyrosine-protein phosphatase non-receptor type 13 Proteins 0.000 description 9
- 101001135619 Homo sapiens Tyrosine-protein phosphatase non-receptor type 5 Proteins 0.000 description 9
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 9
- 101000617278 Homo sapiens Tyrosine-protein phosphatase non-receptor type 7 Proteins 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 9
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 description 9
- 102100033014 Tyrosine-protein phosphatase non-receptor type 13 Human genes 0.000 description 9
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 9
- 102100033259 Tyrosine-protein phosphatase non-receptor type 5 Human genes 0.000 description 9
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 9
- 102100021648 Tyrosine-protein phosphatase non-receptor type 7 Human genes 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 238000007446 glucose tolerance test Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 8
- 238000004896 high resolution mass spectrometry Methods 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000593245 Bionia Species 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 241000907663 Siproeta stelenes Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000002110 toxicologic effect Effects 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 0 COC(C=C(C1C(O2)=O)Oc(c(*)c(C(O)=O)c(O)c3)c3O)=C[C@@]1C2=C* Chemical compound COC(C=C(C1C(O2)=O)Oc(c(*)c(C(O)=O)c(O)c3)c3O)=C[C@@]1C2=C* 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002715 modification method Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 3
- UDWXLZLRRVQONG-UHFFFAOYSA-M sodium hexanoate Chemical compound [Na+].CCCCCC([O-])=O UDWXLZLRRVQONG-UHFFFAOYSA-M 0.000 description 3
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 3
- 239000004324 sodium propionate Substances 0.000 description 3
- 235000010334 sodium propionate Nutrition 0.000 description 3
- 229960003212 sodium propionate Drugs 0.000 description 3
- LHYPLJGBYPAQAK-UHFFFAOYSA-M sodium;pentanoate Chemical compound [Na+].CCCCC([O-])=O LHYPLJGBYPAQAK-UHFFFAOYSA-M 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- OPPLDIXFHYTSSR-GLECISQGSA-N (ne)-n-(1-methylpyrrolidin-2-ylidene)-n'-phenylmorpholine-4-carboximidamide Chemical compound CN1CCC\C1=N/C(N1CCOCC1)=NC1=CC=CC=C1 OPPLDIXFHYTSSR-GLECISQGSA-N 0.000 description 2
- UFJFKQGRZLHOBO-GLECISQGSA-N (ne)-n-(1-methylpyrrolidin-2-ylidene)-n'-phenylpyrrolidine-1-carboximidamide Chemical compound CN1CCC\C1=N/C(N1CCCC1)=NC1=CC=CC=C1 UFJFKQGRZLHOBO-GLECISQGSA-N 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- 229940099563 lactobionic acid Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229950004872 linogliride Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229950005730 pirogliride Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSFNCRAZOCNDJ-UHFFFAOYSA-N propan-2-one Chemical compound CC(C)=O.CC(C)=O YGSFNCRAZOCNDJ-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- YCJBWNIROIXYPD-UHFFFAOYSA-N depsidone Chemical compound O=C1OC2=CC=CC=C2OC2=CC=CC=C12 YCJBWNIROIXYPD-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003509 tertiary alcohols Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a pharmaceutical and food composition for preventing or treating diabetes or obesity, and more specifically, to a novel compound synthesized from a compound isolated from the stereocaulon alpinum extract of Antarctic lichens as an active ingredient. It relates to a pharmaceutical composition and functional food for the prevention or treatment of diabetes or obesity.
- Lichens are known to produce higher plants and other unique secondary metabolites (Ingolfsdottir, K., Phytochemistry, 61: 729, 2002), and the secondary metabolites produced by these lichens are mostly depsides and depsidones ( depsidone) and dibenzfurane, and these compounds are believed to be associated with low growth rates of lichens (Kumar, KCS et al., J. Nat. Prod., 62: 817, 1999; Huneck, S., Naturwissenschaften, 86: 559, 1999).
- diabetes is a metabolic disorder including hyperglycemia caused by a deficiency of insulin action, insulin secretion, or both, and is a disease with high possibility of future vascular complications, and can be broadly divided into type 1 diabetes and type 2 diabetes.
- Type 1 (insulin dependent) diabetes is caused by beta-cell destruction of the pancreatic islets due to immunity and the absolute lack of insulin
- type 2 (insulin-independent) diabetes is not sufficient or is sufficient in insulin. It is caused by the body's inability to utilize insulin secreted effectively.
- the body's energy sources especially sugars, are poorly used, resulting in insufficient energy. Unused sugar is more than necessary in the blood. Accumulated and eventually discharged into the urine is one of the chronic degenerative diseases that do not heal fundamentally.
- Types of diabetes mellitus in Korea account for more than 99%, and the incidence of type 1 diabetes is less than about 1%.
- Type 2 diabetes reported in foreign countries is about 90%, and about 10% It is different from type 1 diabetes.
- the causes of diabetes are intertwined with a variety of factors, and important factors include heredity (approximately 20% of family history), environment, age (approximately 60% between 40-49 years old), obesity, reduced body resistance, drug abuse And stress stimulation.
- the pathogenesis of diabetes has not yet been elucidated, but with the exception of a few specific diabetes mellitus (eg MODY), it is a disease that is caused by multigenic causes, and there is a limit to finding a coherent gene. In other words, the onset of diabetes is complicated by a number of genes and a large number of new genes continue to be identified.
- Diabetes mellitus is caused by a variety of mechanisms, so the treatment also has to vary, moreover, the existing conventional treatments alone do not see a satisfactory effect, so a new treatment is required. Diabetes treatment research has been actively developed with the focus on Type 2 diabetes treatment, which accounts for more than 90% of patients with diabetes (Tables 1 and 2).
- Insulin secretagogues pirogliride, linogliride, 2,4-diaminino-5-cyan-bromoripidine, incretin, repaglinide, nateglinide
- insulin enhancers troglitazone
- insulin resistance enhancers insulin-like effects in target tissues
- Indicating drugs pirogliride, linogliride, dichloroacetate, insulin lispro, insulin aspart
- glucosynthesis inhibitors lipase inhibitors, carnitine transferase inhibitors, beta antioxidants
- drugs that delay carbohydrate absorption dietary fiber, alphaglucocyte
- PTP-1b Protein tyrosine phosphatase-1b activity in adipocytes of people with obesity type and non-obese type 2 diabetes mellitus was tested. Was increased by 3 and 5.5 times, respectively, and activity was reported to be 71% and 88%.
- recent studies have shown that mice knocked out of PTP-1b show increased sensitivity to insulin and resistance to high fat diet.
- substances that inhibit the activity of PTP-1b may overcome insulin resistance by increasing insulin sensitivity in target cells. In Korea, randomized bulk screening is performed to develop inhibitors of PTP-1b activity from tens of thousands of compounds not yet developed as drugs by the Korea Compound Bank.
- leptin is released from the adipocytes into the blood and passes through the cerebral blood membrane, acting on receptors in the central nervous system, inhibiting food intake, weight loss and promoting energy consumption.
- PTP-1b modulates leptin activity itself, it is expected to have synergistic effects when used with leptin agonists (Koren, S., Best Pract. Res. Clin. Endocrinol. Metab). , 21: 621, 2007).
- Stepocaulon alpinum is a salt of a Rover acid (Lobaric acid) isolated from extracts of sodium Rover rate (Sodium Lobarate to develop effective therapeutic agents for diabetes and obesity therapy ) Is not only water soluble and easy to apply, but also newly synthesized Lobarin and Lobarstin inhibit PTP-1b more effectively than Lobaric acid, and PTP in the protein tyrosine dekinase family. Selectively acting only on -1b confirms that the anti-diabetic effect when administered to disease model animals, the present invention was completed.
- An object of the present invention is to provide a pharmaceutical composition and a functional food for preventing or treating diabetes or obesity containing a novel compound synthesized from a compound isolated from a stereocaulon alpinum extract as an active ingredient.
- An object of the present invention is to provide a method for preventing or treating diabetes or obesity, comprising the step of administering a novel compound synthesized from a compound isolated from the stereocaulon alpinum extract.
- An object of the present invention to provide a method for inhibiting the activity of protein tyrosine phosphatase-1b (PTP-1b) comprising the step of administering a novel compound synthesized from a compound isolated from a stereocaulon alpinum extract. .
- PTP-1b protein tyrosine phosphatase-1b
- An object of the present invention is to provide a novel compound synthesized from a compound isolated from the stereocaulon alpinum extract for the prevention or treatment of diabetes or obesity.
- the present invention provides a compound represented by the following formula (1):
- R 1 and R 2 are selected from the group consisting of H, alkyl, aryl, allyl, arylalkyl and acyl groups.
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes or obesity containing the compound represented by Formula 1 as an active ingredient.
- the present invention also provides a food for the prevention or improvement of diabetes or obesity containing the compound represented by the formula (1) as an active ingredient.
- the present invention also provides a compound represented by the following general formula (2):
- the present invention also provides a method for preparing a compound represented by the following Chemical Formula 2, comprising the following steps:
- step (b) eluting the stereocaulon alpinum extract obtained in step (a) with an aqueous solution of methanol or acetonitrile (CH 3 CN) using column chromatography;
- step (c) eluting the fraction eluted in step (b) with acetonitrile (CH 3 CN) or aqueous methanol solution using reverse phase high performance liquid chromatography to obtain a fraction containing lobaric acid;
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes or obesity containing the compound represented by Formula 2 as an active ingredient.
- the present invention also provides a food for preventing or improving diabetes or obesity containing the compound represented by Formula 2 as an active ingredient.
- the present invention also provides a compound represented by Formula 3:
- R 1 and R 2 are selected from the group consisting of H, alkyl, aryl, allyl, arylalkyl and acyl groups.
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes or obesity containing the compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a functional food for preventing or improving diabetes or obesity containing the compound represented by Formula 3 as an active ingredient.
- the present invention also provides a compound represented by the following general formula (4):
- the present invention also provides a method for preparing a compound represented by Formula 4, comprising the following steps:
- step (b) eluting the stereocaulon alpinum extract obtained in step (a) with an aqueous solution of methanol or acetonitrile (CH 3 CN) using column chromatography;
- step (c) eluting the fraction eluted in step (b) with acetonitrile (CH 3 CN) or aqueous methanol solution using reverse phase high performance liquid chromatography to obtain a fraction containing lobaric acid;
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes or obesity containing the compound represented by Formula 4 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a functional food for preventing or improving diabetes or obesity containing the compound represented by Formula 4 as an active ingredient.
- the present invention also provides a compound represented by the following formula (5):
- R 1 and R 2 are selected from the group consisting of H, alkyl, aryl, allyl, arylalkyl and acyl groups.
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes or obesity containing the compound represented by Formula 5 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a functional food for preventing or improving diabetes or obesity containing the compound represented by Formula 5 as an active ingredient.
- the present invention also provides a compound represented by the following general formula (6):
- the present invention also provides a method for preparing a compound represented by Chemical Formula 6, comprising the following steps:
- step (b) eluting the stereocaulon alpinum extract obtained in step (a) with an aqueous solution of methanol or acetonitrile (CH 3 CN) using column chromatography;
- step (c) eluting the fraction eluted in step (b) with acetonitrile (CH 3 CN) or an aqueous methanol solution using reverse phase high performance liquid chromatography to obtain a fraction containing lobaric acid;
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes or obesity containing the compound represented by Formula 6 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a functional food for preventing or improving diabetes or obesity containing the compound represented by Formula 6 as an active ingredient.
- the present invention also provides a step of administering a compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6, which is a novel compound synthesized from a compound isolated from a stereocaulon alpinum extract. It includes, provides a method for preventing or treating diabetes or obesity.
- the present invention also relates to diabetes or obesity of a compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6, which is a novel compound synthesized from a compound isolated from Stereocaulon alpinum extract. It provides a use for the prevention or treatment of.
- the present invention also relates to a PTP- using a compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6, which is a novel compound synthesized from a compound isolated from Stereocaulon alpinum extract. It provides a method of inhibiting the activity of 1b.
- the present invention also provides a PTP-containing compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6, which is a novel compound synthesized from a compound isolated from Stereocaulon alpinum extract.
- a composition for inhibiting activity of 1b is provided.
- Figure 2 shows the 1 H NMR spectrum (400 MHz, DMSO- d 6 ) of sodium lobarate.
- HMBC data 400 MHz, DMSO- d 6 ) of sodium lobarate.
- FIG. 6 is a graph showing the PTP-1b inhibitory activity of sodium lovarate.
- FIG. 7 is a graph showing the absorbance at 620 nm showing the inhibitory activity against PTP-1b, PTPN2, PTPN5, PTPN6, PTPN7, and PTPN13.
- Figure 9 is a graph of the results of blood glucose measurement after 6 hours fasting according to the intraperitoneal administration of sodium lovarate.
- Figure 10 is a graph measuring the change in blood glucose 28 days after intraperitoneal administration of sodium lovarate.
- Figure 13 shows a 1 H NMR spectrum (400 MHz, DMSO- d 6 ) of lovarin.
- Figure 14 shows a 13 C NMR spectrum (400 MHz, DMSO- d 6 ) of lovarin.
- FIG. 16 shows HMBC data (400MHz, DMSO- d 6 ) of lovarin.
- 17 is a graph showing the PTP-1b inhibitory activity of lovarin.
- Fig. 18 is a graph showing the absorbance of lovarin on PTP-1b, PTPN2, PTPN5, PTPN6, PTPN7, and PTPN13 by measuring absorbance at 620 nm.
- 19 is a graph measuring blood glucose change after intraperitoneal administration of lovarin.
- 20 is a graph of blood glucose measurement results after 6 hours fasting according to intraperitoneal administration of lovarin.
- Figure 21 is a graph measuring the change in blood glucose 28 days after intraperitoneal administration of lovarin.
- Figure 25 shows a 13 C NMR spectrum (400 MHz, DMSO- d 6 ) of lovastin.
- FIG. 26 shows COSY data of lovastin (400 MHz, DMSO- d 6 ).
- FIG. 27 shows HSQC data of lovastin (400 MHz, DMSO- d 6 ).
- FIG. 30 is a graph showing the PTP-1b inhibitory activity of lovastin.
- Fig. 31 is a graph showing the absorbance of lovastin to PTP-1b, PTPN2, PTPN5, PTPN6, PTPN7, and PTPN13 by measuring absorbance at 620 nm.
- 32 is a graph measuring blood glucose change after intraperitoneal administration of lovastin.
- 33 is a graph of blood glucose measurement results after 6 hours fasting according to intraperitoneal administration of lovastin.
- 34 is a graph of glucose tolerance test 28 days after intraperitoneal administration of lovastin.
- sodium lobarate represented by the following formula (2) which is a salt of robaric acid, was obtained from robaric acid separated from an extract of stereocaulon alpinum .
- Sodium lovarate represented by the formula (2) is preferably prepared by a method comprising the following steps:
- step (b) eluting the stereocaulon alpinum extract obtained in step (a) with an aqueous solution of methanol or acetonitrile (CH 3 CN) using column chromatography;
- step (c) eluting the fraction eluted in step (b) with acetonitrile (CH 3 CN) or aqueous methanol solution using reverse phase high performance liquid chromatography to obtain a fraction containing lobaric acid;
- step (d) is preferably dissolved in acetone fractions containing the robaric acid, NaHCO 3 , Na 2 CO 3 or NaH 2 PO 4 is added and stirred, NaHCO 3 , Na 2 CO 3 Alternatively, the solid produced simultaneously with addition of NaH 2 PO 4 may be filtered and concentrated to obtain a compound represented by the following Chemical Formula 2.
- the lichen stereocaulon alpinum (Hedw.) GL Sm. Is located around King Sejong Station (S 62 ° 13.3 ', W58 ° 47.0') in King George Island, Antarctica, January 2003. It was taken from Barton Peninsular. Lovaric acid was extracted with dried Stereocaulon alpinum for 24 hours with methanol, and then the solvent was distilled off to obtain an extract. The extract was flash column chromatography filled with silica gel (C 18 ).
- Sodium lovarate of Formula 2 may be obtained by filtering the solid produced simultaneously with addition of NaHCO 3 , Na 2 CO 3 or NaH 2 PO 4 and immediately concentrating it completely with a rotary evaporator.
- R 1 and R 2 are selected from the group consisting of H, alkyl, aryl, allyl, arylalkyl and acyl groups.
- the alkyl group, aryl group, allyl group, arylalkyl group and acyl group may have, for example, 1 to 20 carbon atoms, or 1 to 10 carbon atoms, and the alkyl group includes a substituted, unsubstituted alkyl group, a cycloalkyl group, and the like.
- the compound of Formula 1 is obtained from the sodium lovarate of Formula 2 through a known compound synthesis and modification method known in the art.
- R of the compound of Formula 1 can be obtained various derivatives by changing the number of carbon, the bonding structure.
- R 1 and R 2 are propyl chains, they are derived from the reaction with sodium pentanoate.
- Sodium butyrate, sodium propionate, sodium hexanoate and the like having different carbon numbers can be used to synthesize derivatives having different carbon numbers. .
- sodium lobarate, a salt of lobaric acid, isolated from the extract of stereocaulon alpinum is superior to that of lobaric acid. It has an activity inhibiting activity, and has been confirmed to be effective in preventing or treating diabetes or obesity. Therefore, in another aspect, the present invention relates to a pharmaceutical composition for preventing or treating diabetes or obesity containing sodium lovarate as an active ingredient.
- sodium lobarate according to the present invention may be provided as a functional food containing it as an active ingredient, and thus the present invention, in another aspect, for preventing or improving diabetes or obesity containing sodium lobarate as an active ingredient It relates to a functional food.
- the compound of formula (1) or a pharmaceutically acceptable salt thereof modified with some alkyl groups as follows will also exhibit the same or similar effects, preventing or treating diabetes or obesity containing them It may be provided as a pharmaceutical composition or a functional food.
- the analysis of the inhibitory activity of sodium lovarate against PTP-1b with lovaric acid showed that the IC 50 of lovaric acid was 870 nM, whereas sodium lovarate had a very good PTP- of 50 nM. 1b inhibitory effect, so it was confirmed that sodium lobarate is a drug that can be a pharmaceutical treatment and prevention for diabetes and obesity.
- PTP-1b is the most similar to TC-PTP in the amino acid sequence and 3D structure, induces embrionic lethal, Selectively acts only on PTP-1b of the family of protein tyrosine dekinase containing TC-PTP (PTPN2), which has similar enzymatic properties to TC-PTP and is known to have similar active sites including 2nd aryl-phosphate binding site
- PTPN2 protein tyrosine dekinase containing TC-PTP
- a novel compound represented by the following Chemical Formula 4 was isolated from lovaric acid isolated from the extract of Stereocaulon alpinum , and this was named Lobarin.
- novel compound lovarin represented by Formula 4 may preferably be prepared by a method comprising the following steps:
- step (b) eluting the stereocaulon alpinum extract obtained in step (a) with an aqueous solution of methanol or acetonitrile (CH 3 CN) using column chromatography;
- step (c) eluting the fraction eluted in step (b) with acetonitrile (CH 3 CN) or aqueous methanol solution using reverse phase high performance liquid chromatography to obtain a fraction containing lobaric acid;
- the acidic solution in step (d) can be used for all kinds of acidic solution that can neutralize the aqueous solution, preferably in the step (d) the solvent is acetone, the base is NaOH or KOH, acidic solution May be HCl solution, H 2 SO 4 solution or HNO 3 solution, and the concentrated reaction solution of step (d) is concentrated, and then methylene chloride, methylene chloride, chloroform or It may be characterized by obtaining a chloroform or ethylene chloride dissolved layer and concentrating to obtain a compound represented by the following formula (4).
- the solvent is acetone
- the base is NaOH or KOH
- acidic solution May be HCl solution, H 2 SO 4 solution or HNO 3 solution
- the concentrated reaction solution of step (d) is concentrated, and then methylene chloride, methylene chloride, chloroform or It may be characterized by obtaining a chloroform or ethylene chloride dissolved layer and concentrating to obtain a compound represented by the following formula (4).
- R 1 and R 2 are selected from the group consisting of H, alkyl, aryl, allyl, arylalkyl and acyl groups.
- the alkyl group, aryl group, arylalkyl group and acyl group may be, for example, 1 to 20 carbon atoms, or 1 to 10, the alkyl group includes a substituted, unsubstituted alkyl group, cyclo alkyl group and the like.
- R of the compound of Formula 3 may be obtained various derivatives by changing the number of carbon, the bond structure.
- R 1 and R 2 are propyl chains, they are derived from the reaction with sodium pentanoate.
- Sodium butyrate, sodium propionate, sodium hexanoate and the like having different carbon numbers can be used to synthesize derivatives having different carbon numbers. .
- the present invention relates to a pharmaceutical composition for preventing or treating diabetes or obesity containing lovarin of Formula 4 or a pharmaceutically acceptable salt thereof as an active ingredient.
- lovarin according to the present invention may be provided as a functional food containing it as an active ingredient, and thus the present invention, in another aspect, a functional food for the prevention or improvement of diabetes or obesity containing lovarin as an active ingredient It is about.
- the compound of the formula (3) or a pharmaceutically acceptable salt thereof modified with some alkyl groups as follows will also exhibit the same or similar effects, for the prevention or treatment of diabetes or obesity containing them It may be provided as a pharmaceutical composition, a functional food.
- the anti-diabetic effect was verified by determining the correlation between blood glucose and insulin resistance by measuring glubarine and db / db mice, the disease animal models, by measuring changes in blood glucose and blood insulin concentration. .
- the lovarin of the general formula (4) used in the present invention may be in the form of a pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts in the present invention can be prepared by conventional methods in the art, for example, salts with inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid, sodium hydrogen sulfate, phosphoric acid, carbonic acid, and the like.
- a pharmaceutically acceptable acid together with an organic acid such as formic acid, acetic acid, oxalic acid, benzoic acid, citric acid, tartaric acid, gluconic acid, gestyic acid, fumaric acid, lactobionic acid, salicylic acid, or acetylsalicylic acid (aspirin) Salts may be formed, or they may be reacted with alkali metal ions such as sodium or potassium to form their metal salts, or they may be reacted with ammonium ions to form another form of a pharmaceutically acceptable salt.
- an organic acid such as formic acid, acetic acid, oxalic acid, benzoic acid, citric acid, tartaric acid, gluconic acid, gestyic acid, fumaric acid, lactobionic acid, salicylic acid, or acetylsalicylic acid (aspirin) Salts may be formed, or they may be reacted with alkali metal ions such as sodium or potassium to form their metal
- a novel compound represented by the following Chemical Formula 6 was isolated from lovaric acid isolated from an extract of Stereocaulon alpinum , which was named Lobarstin.
- novel compound lovastin represented by Formula 6 may preferably be prepared by a method comprising the following steps:
- step (b) eluting the stereocaulon alpinum extract obtained in step (a) with an aqueous solution of methanol or acetonitrile (CH 3 CN) using column chromatography;
- step (c) eluting the fraction eluted in step (b) with acetonitrile (CH 3 CN) or an aqueous methanol solution using reverse phase high performance liquid chromatography to obtain a fraction containing lobaric acid;
- the acidic solution in step (d) can be used for all kinds of acidic solution that can neutralize the aqueous solution, preferably in the step (d) the solvent is acetone, the base is NaOH or KOH, acidic solution May be HCl solution, H 2 SO 4 solution or HNO 3 solution, and the concentrated reaction solution of step (d) is concentrated, and then methylene chloride, methylene chloride, chloroform or It may be characterized by obtaining a chloroform or ethylene chloride dissolved layer and concentrating to obtain a compound represented by the following formula (6).
- the solvent is acetone
- the base is NaOH or KOH
- acidic solution May be HCl solution, H 2 SO 4 solution or HNO 3 solution
- the concentrated reaction solution of step (d) is concentrated, and then methylene chloride, methylene chloride, chloroform or It may be characterized by obtaining a chloroform or ethylene chloride dissolved layer and concentrating to obtain a compound represented by the following formula (6).
- R 1 and R 2 are selected from the group consisting of H, alkyl, aryl, allyl, arylalkyl and acyl groups.
- the alkyl group, aryl group, allyl group arylalkyl group and acyl group may be, for example, 1 to 20 carbon atoms, or 1 to 10, the alkyl group includes a substituted, unsubstituted alkyl group, cyclo alkyl group and the like.
- R of the compound of Formula 5 may obtain various derivatives through the change in the number of carbons and the bonding structure.
- R 1 and R 2 are propyl chains, they are derived from the reaction with sodium pentanoate. Sodium butyrate, sodium propionate, sodium hexanoate and the like having different carbon numbers can be used to synthesize derivatives having different carbon numbers. .
- lovastin a novel derivative of lovaric acid isolated from the extract of Stereocaulon alpinum , has an excellent activity of inhibiting the activity of PTP-1b, and thus it is confirmed that it is effective in preventing or treating diabetes or obesity.
- the present invention relates to a pharmaceutical composition for preventing or treating diabetes or obesity containing lovastin of Formula 6 or a pharmaceutically acceptable salt thereof as an active ingredient.
- lovastin according to the present invention may be provided as a functional food containing the same as an active ingredient, the present invention in another aspect, to prevent or improve the functional food for diabetes or obesity containing lovastin as an active ingredient It is about.
- the compound of the formula (5) or a pharmaceutically acceptable salt thereof modified with some alkyl groups as shown below will also exhibit the same or similar effects, for the prevention or treatment of diabetes or obesity containing them It may be provided as a pharmaceutical composition, a functional food.
- the anti-diabetic effect was verified by determining the correlation between blood glucose and insulin resistance by measuring glustatin and blood insulin concentrations by administering lovastin to a disease animal model db / db mouse. .
- lovastin of the formula (6) used in the present invention may be in the form of a pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts in the present invention can be prepared by conventional methods in the art, for example, salts with inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid, sodium hydrogen sulfate, phosphoric acid, carbonic acid, and the like.
- a pharmaceutically acceptable acid together with an organic acid such as formic acid, acetic acid, oxalic acid, benzoic acid, citric acid, tartaric acid, gluconic acid, gestyic acid, fumaric acid, lactobionic acid, salicylic acid, or acetylsalicylic acid (aspirin) Salts may be formed, or they may be reacted with alkali metal ions such as sodium or potassium to form their metal salts, or they may be reacted with ammonium ions to form another form of a pharmaceutically acceptable salt.
- an organic acid such as formic acid, acetic acid, oxalic acid, benzoic acid, citric acid, tartaric acid, gluconic acid, gestyic acid, fumaric acid, lactobionic acid, salicylic acid, or acetylsalicylic acid (aspirin) Salts may be formed, or they may be reacted with alkali metal ions such as sodium or potassium to form their metal
- compositions comprising the compounds according to the invention, respectively, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, external preparations, suppositories and sterile injectable solutions according to conventional methods.
- Carriers, excipients and diluents that may be included in the composition comprising the compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose, gelatin and the like.
- excipients such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose, gelatin and the like.
- lubricants such as magnesium stearate and talc are also used.
- Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- As the base of the suppository witepsol, macrogol, tween 60, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the functional food of the present invention includes various foods, candy, chocolate, beverages, gums, teas, vitamin complexes, health supplements, and the like, and can be used in the form of powders, granules, tablets, capsules or beverages.
- the compounds of the present invention may be added to foods or beverages for the purpose of preventing diabetes and obesity.
- the amount of the compound in the food or beverage is generally added to the dietary supplement composition of the present invention to 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight, the health beverage composition is 100 ml It can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g as a reference.
- the health beverage composition of the present invention has no particular limitation on the liquid component except for containing the compound of the present invention as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
- natural carbohydrates include monosaccharides such as glucose, fructose and the like, disaccharides such as maltose, sucrose and the like, conventional sugars such as polysaccharides such as dextrin, cyclodextrin and xylitol Sugar alcohols such as sorbitol and erythritol.
- natural flavoring agents such as sorbitol and erythritol.
- the ratio is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention, in addition to the above, the functional food of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors.
- Flavoring agents coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated drinks Carbonic acid used, etc.
- the functional food of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages.
- the ratio of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
- the present invention provides a compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5, or Formula 6, which is a novel compound synthesized from a compound isolated from Stereocaulon alpinum extract. It relates to a method for preventing or treating diabetes or obesity, comprising the step of administering.
- Preferred dosages of the compounds of the present invention depend on the condition and weight of the patient, the extent of the disease, the form of the drug, the route and duration of the patient. It depends, but can be appropriately selected by those skilled in the art. However, for the preferred effect, the compound of the present invention is preferably administered at 0.1 to 1000 ⁇ g / kg, preferably at 1 to 100 ⁇ g / kg. Administration may be administered once a day or may be divided orally. The dosage does not limit the scope of the invention in any aspect.
- the present invention is a novel compound synthesized from a compound isolated from Stereocaulon alpinum extract of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6 It relates to the use for the prevention or treatment of diabetes or obesity.
- the present invention since sodium lovarate, lovarin, and lovastin synthesized from a compound isolated from a stereocaulon alpinum extract have excellent inhibitory effects on PTP-1b activity, a method of inhibiting the activity of PTP-1b using the same It is about. Specifically, the present invention relates to a method for inhibiting activity of PTP-1b comprising administering to a subject a compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6.
- the present invention relates to a PTP-1b containing a compound represented by Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6, which is a new compound synthesized from a compound isolated from Stereocaulon alpinum extract. It relates to a composition for inhibiting activity.
- Example 1-2 10 mg (22 umol) of lobaric acid obtained in Example 1-2 was dissolved in 3 ml of acetone, and 50ul of 1M NaHCO 3 was added, followed by stirring for 1-2 minutes. The solid produced simultaneously with NaHCO 3 addition was filtered and concentrated immediately by rotary evaporator. When concentration is complete, a white solid, sodium lovarate ( ⁇ 10 mg) is obtained. It was then analyzed by reverse phase HPLC using an Agilent Eclipse XDB-C18 column (4.6 x 150 mm, USA) to remove excess salt to increase purity. The solvent system used was 0.1% formic acid mixed water (A Line) and 0.1% formic acid mixed acetonitrile (B line).
- the structure of sodium lobarate was confirmed by comparing the NMR data of the compound with the NMR data of lobaric acid.
- PTP-1b protein tyrosine phosphatase-1b
- PTP-1b (Bionia, Korea), PTP-1b buffer solution (20 mM Tris-Hcl, pH 8.0, 0.75 mM NaCl, 0.5 mM EDTA, 5 mM ⁇ -mercaptoethanol, 50% Glycerol) Sodium lovarate 0, 1, 3, 10, 30, 100, 300, 1000, 3000 nM and the substrate [pTyr1146] Insulin Receptor (1142-1153, Sigma, USA) were added and then reacted at room temperature for 10-30 minutes.
- PTP-1b inhibitory activity of lobaric acid was measured and compared as a control.
- PTP-1b was purchased from BIOMOL (USA) and used for experiments.
- PTP-1b and PTP-1b buffer solutions 50 mM citrate) at a concentration of about 0.2 ⁇ g / ml , pH 6.0, 0.1M NaCl, 1 mM EDTA, 1 mM DTT), lobaric acid, 4 mM pNPP were added and gently shaken, reacted at 37 ° C. for 30 minutes, and the absorbance was measured at 405 nm.
- IC 50 0.87 It was confirmed that the ⁇ M, 870nM.
- the sodium lobarate according to the present invention has a superior PTP-1b inhibitory effect, and the sodium lobarate is a substance capable of pharmaceutical treatment and prevention of diabetes and obesity.
- TC-PTP TC-PTP
- TC-PTP (PTPN2), known to be the most similar kinase to PTP-1b in its amino acid sequence and 3D structure, is an embrionic lethal and has an enzymatic characteristic similar to that of PTP-1b and has an active site containing a 2nd aryl-phosphate binding site. It is known to be similar.
- PTPN2 TC-PTP
- Doses (expressed in test substance (mg) / weight of test animal (Kg)) were determined based on preliminary, potent, toxicological, and data studies on sodium lovarate. Seven-week-old male db / db mice (type 2 diabetes model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology) were treated with 200 ⁇ l of PBS as a control and sodium lovaba as an experimental inhibitor. A 10 mg / kg rate was intraperitoneally administered daily to measure blood glucose twice a week.
- PBS 200 was used as a control in 7-week-old male db / db mice (type 2 diabetes model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology). After the intraperitoneal injection of sodium lovarate 10 mg / kg into the experimental group daily, blood glucose was measured twice a week. At this time, after fasting for 6 hours after the intraperitoneal injection blood glucose was measured.
- IPGTT Intraperitoneal glucose tolerance test
- mice type 2 diabetes model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology
- physiological saline as a control
- sodium lovarate 10mg / kg as an experimental group for 28 days.
- glucose 500 mg / ml, administration volume 200 ⁇ l
- Example 5 show that sodium lobarate according to the present invention has a very good antidiabetic effect.
- Example 6 The molecular structure of lovarin synthesized in Example 6 was characterized by high resolution mass spectrometry (HRESIMS) and NMR spectroscopy.
- HRESIMS high resolution mass spectrometry
- NMR spectroscopy The molecular structure of lovarin synthesized in Example 6 was characterized by high resolution mass spectrometry (HRESIMS) and NMR spectroscopy.
- HRESIMS HRESIMS
- lovarin showed a molecular ion peak of m / z 473.1774, which is lovarin. It is shown that the molecular formula of C 25 H 30 O 9 .
- HMQC data (FIG. 15) and HMBC data (FIG. 16) confirmed the location of the peaks for each carbon and hydrogen of lobulin, and these data were similar to the NMR measurements of lovalic acid.
- HMBC correlations from the peak corresponding to the protons of the OH functional group (7.65 ppm) to the 13 C NMR peaks corresponding to the C-6, C-7, and C-8 positions are important data to elucidate the structure of the presented lovarin. Provided.
- aHMBC correlations optimized for 8 Hz, are from proton (s) stated to the indicated carbon (s).
- PTP-1b (Bionia, Korea), PTP-1b buffer solution (20 mM Tris-Hcl, pH 8.0, 0.75 mM NaCl, 0.5 mM EDTA, 5 mM ⁇ -mercaptoethanol, 50% Glycerol)
- PTP-1b buffer solution 20 mM Tris-Hcl, pH 8.0, 0.75 mM NaCl, 0.5 mM EDTA, 5 mM ⁇ -mercaptoethanol, 50% Glycerol
- lovarin 0, 1, 3, 10, 30, 100, 300, 1000, 3000 nM and the substrate [pTyr1146] Insulin Receptor (1142-1153, Sigma, USA) and reacted at room temperature for 10-30 minutes.
- Malachite Green-Molybdate Dye Solution (1142-1153, Sigma, USA) was added to react at room temperature for 10 minutes to terminate the reaction with PTP-1b, lovarin and substrate, the absorbance was measured at 620 nm.
- lobulin showed an inhibition rate of 52.2% at 200 nM of IC 50 against PTP-1b, especially TC-PTP (PTPN2). There was no inhibitory activity against other protein tyrosine kinase families.
- Doses (expressed as test substance (mg) / weight of test animal (Kg)) were determined based on preliminary, potent, toxicological, and data for lovarin. Seven-week-old male db / db mice (type 2 diabetic model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology) were intraperitoneally administered 200 ⁇ l of PBS as a control and 10 mg / kg of lovarin as experimental groups daily. Blood glucose was measured twice a week.
- IPGTT intraperitoneal glucose tolerance test
- mice type 2 diabetic model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology
- 20% DMSO as a control
- 10 mg / kg of lovarin daily as experimental groups.
- fasting glucose 500 mg / ml, administration volume 200 ⁇ l
- intraperitoneal injection after 16 hours without 20% DMSO and lovarin, respectively, 0, 15, 30, 60 Blood glucose changes were observed in blood samples taken from the tail vein at 90 and 120 minutes.
- HRESIMS high resolution mass spectrometry
- NMR spectroscopy NMR spectroscopy
- Anion analysis of HRESIMS was measured using a Q-TOF micro LC-MS / MS instrument (Waters, USA).
- lovastin showed a molecular ion peak of m / z 455.1708, which is lovastin. It is shown that the molecular formula of is C 25 H 28 O 8 .
- HMBC Heteronuclear Multiple-Bond Coherence
- the structure of lovastin has a structure very similar to that of lovarin, and considering that the difference in molecular weight is 18 dalton, it could be predicted that the compound was produced through the removal reaction of water molecules from lovarin.
- sp 3 hybrid carbons C-8 of lovastin
- sp 3 hybrid carbons exhibit absorption peaks, especially in the low field shifted observed in lovalin in the 13 C NMR spectrum. , 106.3 ppm) and the absorption peaks of aliphatic methylene carbon disappeared and instead the absorption peaks observed in the two double bond regions were observed.
- HMBC data confirmed the location of the peaks corresponding to the respective carbon and hydrogen of lovastin, especially from H-5, 9, 10 and 11 in the lovastin structure.
- HMBC correlations provided important data to elucidate the structure of lovastin presented.
- the geometric conformation of the double bonds formed in C-8 and C-9 was Z-type (cis-type) based on the observation of NOE correlation between H-5 and H-9 (FIG. 29).
- aHMBC correlations optimized for 8 Hz, are from proton (s) stated to the indicated carbon (s).
- the enzyme activity was measured spectroscopically. That is, 0.5 mg / ml PTP-1b (Bionia, Korea), PTP-1b buffer solution (20 mM Tris-Hcl, pH 8.0, 0.75 mM NaCl, 0.5 mM EDTA, 5 mM ⁇ -mercaptoethanol, 50% Glycerol) To lovastin 0, 1, 3, 10, 30, 100, 300, 1,000, 3,000 nM and the substrate [pTyr1146] Insulin Receptor (1142-1153, Sigma, USA) were added and then reacted at room temperature for 10-30 minutes.
- IC 50 154.6 nM showed excellent PTP-1b inhibitory effect, it was confirmed that the inhibition rate increased depending on the concentration It was confirmed that the drug is capable of pharmacological treatment and prevention of diabetes and obesity.
- the IC 50 inhibition rate of PTP-1b at 200 nM lovastin was 47.96%, particularly TC-PTP (PTPN2).
- PTPN2 TC-PTP
- Doses (expressed as test substance (mg) / weight of test animal (Kg)) were determined based on preliminary, potent, toxicological, and data for lovastin. Seven-week-old male db / db mice (type 2 diabetes model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology) were intraperitoneally administered 200 ⁇ l of PBS as a control and 10 mg / kg of lovastin as experimental groups daily. Blood glucose was measured twice a week.
- lovastin For more accurate antidiabetic effect on lovastin, 200 ⁇ l of PBS was used as a control in 7-week-old male db / db mice (type 2 diabetes model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology). After the intraperitoneal injection of lovastin 10 mg / kg daily in the experimental group, blood glucose was measured twice a week. At this time, after fasting for 6 hours after the intraperitoneal injection blood glucose was measured.
- IPGTT Intraperitoneal glucose tolerance test
- mice type 2 diabetic model animals, C57 / BLKS / J-db / db, Korea Research Institute of Bioscience and Biotechnology
- 20% DMSO as a control
- 10 mg / kg of lovastin as experimental groups.
- glucose 500 mg / ml, administration volume 200 ⁇ l
- blood glucose changes were observed in blood samples taken from the tail vein at 60, 90 and 120 minutes.
- the novel compound according to the present invention is very excellent in PTP-1b (protein tyrosine phosphatase-1b) inhibitory activity, selectively acts only on PTP-1b of the protein tyrosine dephosphatase family, and is a substantial PTP-1b inhibitor. Available for the treatment of diabetes, effective for the prevention or treatment of diabetes and obesity.
- PTP-1b protein tyrosine phosphatase-1b
Abstract
Description
Claims (26)
- 다음의 단계를 포함하는 하기 화학식 2로 표시되는 화합물의 제조방법:(a) 스테레오카울론 알피넘 (Stereocaulon alpinum)을 메탄올로 추출하는 단계;(b) (a)단계에서 수득된 스테레오카울론 알피넘 (Stereocaulon alpinum) 추출물을 컬럼크로마토그래피를 이용하여 메탄올 또는 아세토니트릴 (CH3CN) 수용액으로 용출하는 단계;(c) (b)단계에서 용출된 분획물을 역상 고속 액체 크로마토그래피를 이용하여 아세토니트릴 (CH3CN) 또는 메탄올 수용액으로 용출시켜 로바릭산 (Lobaric acid)을 함유하는 분획을 수득하는 단계; 및(d) 상기 로바릭산을 함유하는 분획을 용매에 용해한 후, NaHCO3, Na2CO3 또는 NaH2PO4를 첨가하고 교반한 다음, 하기 화학식 2로 표시되는 화합물을 수득하는 단계화학식 2
- 다음의 단계를 포함하는 하기 화학식 4로 표시되는 화합물의 제조방법:(a) 스테레오카울론 알피넘 (Stereocaulon alpinum)을 메탄올로 추출하는 단계;(b) (a)단계에서 수득된 스테레오카울론 알피넘 (Stereocaulon alpinum) 추출물을 컬럼크로마토그래피를 이용하여 메탄올 또는 아세토니트릴 (CH3CN) 수용액으로 용출하는 단계;(c) (b)단계에서 용출된 분획물을 역상 고속 액체 크로마토그래피를 이용하여 아세토니트릴 (CH3CN) 또는 메탄올 수용액으로 용출시켜 로바릭산 (Lobaric acid)을 함유하는 분획을 수득하는 단계; 및(d) 상기 로바릭산을 함유하는 분획을 용매에 용해한 후, 염기를 첨가하고 교반한 다음, 산성용액을 첨가하여 반응을 종결시킨 후, 하기 화학식 4로 표시되는 화합물을 수득하는 단계.화학식 4
- 제11항에 있어서, 상기 (d) 단계에서 용매는 아세톤이고, 염기는 NaOH 또는 KOH이며, 산성용액은 HCl 용액, H2SO4 용액 또는 HNO3 용액인 것을 특징으로 하는 방법.
- 다음의 단계를 포함하는 하기 화학식 6으로 표시되는 화합물의 제조방법:(a) 스테레오카울론 알피넘 (Stereocaulon alpinum)을 메탄올로 추출하는 단계;(b) (a)단계에서 수득된 스테레오카울론 알피넘 (Stereocaulon alpinum) 추출물을 컬럼크로마토그래피를 이용하여 메탄올 또는 아세토니트릴 (CH3CN) 수용액으로 용출하는 단계;(c) (b)단계에서 용출된 분획물을 역상 고속 액체 크로마토그래피를 이용하여 아세토니트릴 (CH3CN) 또는 메탄올 수용액으로 용출시켜 로바릭산을 함유하는 분획을 수득하는 단계; 및(d) 상기 로바릭산을 함유하는 분획을 용매에 용해한 후, 물과 염기를 첨가하고 교반한 다음, 산성용액을 첨가하여 반응을 종결시킨 후, 하기 화학식 6으로 표시되는 화합물을 수득하는 단계화학식 6
- 제20항에 있어서, 상기 (d) 단계에서 용매는 아세톤이고, 염기는 NaOH 또는 KOH이며, 산성용액은 HCl 용액, H2SO4 용액 또는 HNO3 용액인 것을 특징으로 하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/878,196 US8846750B2 (en) | 2010-10-07 | 2011-07-01 | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
EP11830831.1A EP2626070B1 (en) | 2010-10-07 | 2011-07-01 | Pharmaceutical and food composition for preventing or treating diabetes or obesity |
CN2011800591843A CN103249410A (zh) | 2010-10-07 | 2011-07-01 | 预防或治疗糖尿病或肥胖症的药物组合物和食品组合物 |
JP2013532710A JP5755749B2 (ja) | 2010-10-07 | 2011-07-01 | 糖尿病若しくは肥満の予防、または治療用医薬組成物及び食品組成物 |
US13/900,361 US8703814B1 (en) | 2010-10-07 | 2013-05-22 | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
US13/900,155 US8697745B2 (en) | 2010-10-07 | 2013-05-22 | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0097677 | 2010-10-07 | ||
KR20100097678A KR101481140B1 (ko) | 2010-10-07 | 2010-10-07 | 신규 화합물 로바린을 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물 |
KR10-2010-0097678 | 2010-10-07 | ||
KR20100097677A KR101485162B1 (ko) | 2010-10-07 | 2010-10-07 | 소듐 로바레이트를 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물 |
KR10-2011-0039155 | 2011-04-26 | ||
KR20110039155A KR101481141B1 (ko) | 2011-04-26 | 2011-04-26 | 신규 화합물 로바스틴을 함유하는 당뇨병 예방 또는 치료용 약학 조성물 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/878,196 A-371-Of-International US8846750B2 (en) | 2010-10-07 | 2011-07-01 | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
US13/900,155 Division US8697745B2 (en) | 2010-10-07 | 2013-05-22 | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
US13/900,361 Division US8703814B1 (en) | 2010-10-07 | 2013-05-22 | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012046945A2 true WO2012046945A2 (ko) | 2012-04-12 |
WO2012046945A3 WO2012046945A3 (ko) | 2012-06-14 |
Family
ID=45928177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/004836 WO2012046945A2 (ko) | 2010-10-07 | 2011-07-01 | 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8846750B2 (ko) |
EP (2) | EP2617464B1 (ko) |
JP (2) | JP5755749B2 (ko) |
CN (2) | CN103249410A (ko) |
WO (1) | WO2012046945A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065545A1 (ko) * | 2012-10-24 | 2014-05-01 | 한국해양과학기술원 | 로바스틴을 함유하는 뇌암의 예방 또는 치료용 약학 조성물 및 이를 이용한 뇌암의 치료를 위한 병용요법 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703814B1 (en) | 2010-10-07 | 2014-04-22 | Korea Ocean Research And Development Institute | Pharmaceutical and food compositions for preventing or treating diabetes or obesity |
CN104059049A (zh) * | 2013-03-21 | 2014-09-24 | 华东师范大学 | 具有光学活性的苯并二氧杂环衍生物及其制备方法和应用 |
RU2613271C1 (ru) * | 2015-12-24 | 2017-03-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет имени М.К. Аммосова" | Способ коррекции метаболических нарушений при сахарном диабете второго типа |
CN106176834A (zh) * | 2016-08-28 | 2016-12-07 | 成都宝科生物科技有限公司 | 一种用于治疗糖尿病的地衣提取物 |
KR102022543B1 (ko) * | 2017-12-29 | 2019-09-18 | 한국해양과학기술원 | 로바릭산 및 그 유사체의 합성방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198815A1 (en) * | 2003-03-31 | 2004-10-07 | Council Of Scientific And Industrial Research | Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum) |
WO2008156654A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
US20090048332A1 (en) | 2007-08-14 | 2009-02-19 | Hej Research Insitute | Natural Novel Antioxidants |
KR100957203B1 (ko) * | 2007-11-14 | 2010-05-11 | 한국해양연구원 | 단백질 타이로신 탈인산화효소 1b의 활성 억제능을 갖는스테레오카울론 알피넘 추출물 및 이로부터 분리된우스닉산 유도체 |
KR101185137B1 (ko) * | 2009-04-07 | 2012-09-24 | 한국해양연구원 | 스테레오카울론 알피넘 유래 화합물을 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물 |
-
2011
- 2011-07-01 EP EP13164471.8A patent/EP2617464B1/en active Active
- 2011-07-01 CN CN2011800591843A patent/CN103249410A/zh active Pending
- 2011-07-01 CN CN201510552764.6A patent/CN105175371B/zh active Active
- 2011-07-01 EP EP11830831.1A patent/EP2626070B1/en active Active
- 2011-07-01 US US13/878,196 patent/US8846750B2/en active Active
- 2011-07-01 JP JP2013532710A patent/JP5755749B2/ja active Active
- 2011-07-01 WO PCT/KR2011/004836 patent/WO2012046945A2/ko active Application Filing
-
2015
- 2015-04-07 JP JP2015078174A patent/JP2015212255A/ja active Pending
Non-Patent Citations (9)
Title |
---|
"Pharmaceutical Industry White Paper", December 2004, KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE |
"Recent Trends in Studies on Diabetes Therapeutic Agents", TRENDS IN HEALTH INDUSTRY & TECHNOLOGY, 2003 |
BARTON PENINSULA ON KING GEORGE ISLAND, January 2003 (2003-01-01) |
HUNECK, S., NATURWISSENSCHAFTEN, vol. 86, 1999, pages 559 |
INGOLFSDOTTIR, K., PHYTOCHEMISTRY, vol. 61, 2002, pages 729 |
KOREN, S., BEST PRACT. RES. CLIN. ENDOCRINOL. METAB., vol. 21, 2007, pages 621 |
KUMAR, K.C.S. ET AL., J. NAT. PROD., vol. 62, 1999, pages 817 |
LIU, S. ET AL., J. AM. CHEM. SOC., vol. 130, 2008, pages 17075 |
See also references of EP2626070A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065545A1 (ko) * | 2012-10-24 | 2014-05-01 | 한국해양과학기술원 | 로바스틴을 함유하는 뇌암의 예방 또는 치료용 약학 조성물 및 이를 이용한 뇌암의 치료를 위한 병용요법 |
KR20140052396A (ko) * | 2012-10-24 | 2014-05-07 | 한국해양과학기술원 | 로바스틴을 함유하는 뇌암의 예방 또는 치료용 약학 조성물 및 이를 이용한 뇌암의 치료를 위한 병용요법 |
KR101892078B1 (ko) | 2012-10-24 | 2018-08-28 | 한국해양과학기술원 | 로바스틴을 함유하는 뇌암의 예방 또는 치료용 약학 조성물 및 이를 이용한 뇌암의 치료를 위한 병용요법 |
Also Published As
Publication number | Publication date |
---|---|
EP2626070A2 (en) | 2013-08-14 |
US8846750B2 (en) | 2014-09-30 |
CN103249410A (zh) | 2013-08-14 |
JP2013543503A (ja) | 2013-12-05 |
EP2626070A4 (en) | 2014-04-09 |
JP2015212255A (ja) | 2015-11-26 |
JP5755749B2 (ja) | 2015-07-29 |
WO2012046945A3 (ko) | 2012-06-14 |
US20130261174A1 (en) | 2013-10-03 |
EP2626070B1 (en) | 2018-01-24 |
EP2617464A1 (en) | 2013-07-24 |
CN105175371B (zh) | 2018-03-13 |
EP2617464B1 (en) | 2016-06-15 |
CN105175371A (zh) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012046945A2 (ko) | 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물 | |
WO2017030410A1 (ko) | 검정콩잎 추출물 및 이로부터 분리한 플라보놀배당체를 유효성분으로 함유하는 대사증후군의 예방 또는 치료용, 또는 항산화용 조성물 | |
WO2011083999A2 (ko) | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
WO2018124508A1 (ko) | 3,5-디카페오일퀴닉에시드 또는 국화 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 | |
WO2022035115A1 (ko) | 오리나무 추출물 또는 이로부터 분리된 화합물을 함유하는 골격근 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2014175543A1 (ko) | 복합 추출물을 포함하는 대장염 예방, 개선 또는 치료용 조성물 | |
WO2019212196A1 (ko) | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 | |
WO2015099392A1 (ko) | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 | |
WO2009125923A2 (en) | Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | |
WO2013183920A1 (ko) | 베르베논 유도체를 함유하는 퇴행성 뇌질환 치료 또는 예방용 약학 조성물 | |
WO2014027832A1 (ko) | 대장염 예방 또는 치료용 조성물 | |
WO2012067316A1 (ko) | 테로카판계 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 대사성 질환 또는 이들의 합병증의 예방 또는 치료용, 또는 항산화용 조성물 | |
WO2014007447A1 (ko) | 하이드록시 챨콘 화합물을 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 조성물 | |
WO2018004263A1 (ko) | 광학 활성 피라노크로메닐페놀 유도체 및 그를 포함하는 약학적 조성물 | |
WO2010090498A2 (ko) | 이고들빼기 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 간 기능 개선용 약학적 조성물 및 간 기능 개선용 건강기능 식품조성물 | |
WO2011122815A2 (en) | Novel quinoxaline derivatives | |
WO2018008803A1 (ko) | 세스퀴테르펜 유도체의 신규한 용도 | |
WO2020050462A1 (ko) | 결명 새싹 유래 나프토파이론 유도체를 포함하는 신경세포 보호용 조성물 | |
WO2019194583A1 (ko) | 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물 | |
WO2021187766A1 (ko) | P38 제거능을 갖는 화합물, 이의 제조방법 및 이를 포함하는 만성 염증성 질환 치료용 조성물 | |
WO2021230710A1 (ko) | 신규 ido/tdo 억제제, 그의 항암 용도, 그의 항암 병용 요법 | |
WO2020080641A1 (ko) | 지노스테마 론기페스 vk1 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 ampk 관련 질환 예방 또는 치료용 조성물 | |
WO2018217009A1 (ko) | 신선초 추출물 또는 이로부터 분리된 화합물을 함유하는 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2020139001A1 (ko) | 세포 내 atp 생성 촉진을 위한 약제학적 조성물 | |
WO2018016901A1 (ko) | 골질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11830831 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011830831 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013532710 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13878196 Country of ref document: US |